| Primary care | Outpatient clinic | P value | |
---|---|---|---|---|
Number of participants | 1056 | 830 | Â | |
Female sex, n (%) | 494 (46.8) | 380 (45.9) | 0.71 | |
Age, year, median (IQR) | 65.5 (58.1–72.9) | 65.9 (58.9–72.9) | 0.66 | |
Age of onset diabetes, year, median (IQR) | 59 (51–67) | 51 (44–59) | <0.001 | |
Duration of diabetes, year, median (IQR) | 4.5 (1.2–7.9) | 12.5 (7.2–17.8) | <0.001 | |
BMI, kg/m2, median (IQR) | 29.0 (26.0–32.0) | 30.2 (26.8–33.7) | <0.001 | |
HbA1c, mmol/mol, median (IQR) | 48.6 (43.7–53.6) | 56.3 (48.1–64.5) | <0.001 | |
Diabetes treatment, % (n/n-available/n-missing) | ||||
 No medication | 24.7 (248/1004/52) | 12.0 (92/768/62) | <0.001 | |
 Oral glucose-lowering agents | 72.9 (732/1004/52) | 53.1 (408/768/62) | <0.001 | |
 Insulin | 8.6 (86/1004/52) | 63.3 (486/768/62) | <0.001 | |
Systolic blood pressure, mmHg, median (IQR) | 146 (133–159) | 134 (126–143) | <0.001 | |
Diastolic blood pressure, mmHg, median (IQR) | 79 (72–86) | 75 (70–80) | <0.001 | |
Total cholesterol, mmol/L, median (IQR) | 4.2 (3.6–4.9) | 4.1 (3.6–4.6) | 0.047 | |
Triglycerides, mmol/L, median (IQR) | 1.4 (0.9–1.9) | 1.5 (1.0–2.0) | 0.104 | |
HDL-cholesterol, mmol/L, median (IQR) | 1.1 (0.9–1.3) | 1.2 (1.0–1.4) | 0.002 | |
LDL-cholesterol, mmol/L, median (IQR) | 2.5 (2.0–3.1) | 2.1 (1.7–2.6) | <0.001 | |
Creatinine, µmol/L, median (IQR) | 76 (64–88) | 81 (67–95) | <0.001 | |
eGFRÂ <Â 60Â mL/min % (n/n available/n-missing) | 16.4 (160/978/78) | 27.2 (212/778/52) | <0.001 | |
Cardiovascular disease, % (n/n-available/n-missing) | ||||
 Any macrovascular disease | 34.8 (335/963/93) | 41.9 (325/775/55) | 0.002 | |
 Ischemic heart disease | 25.2 (252/1000/56) | 31.5 (245/778/52) | 0.004 | |
 Ischemic brain disease | 12.7 (124/973/83) | 11.1 (87/784/46) | 0.302 | |
 Peripheral arterial disease | 9.2 (88/958/98) | 12.7 (105/825/5) | 0.0181 | |
Microvascular diabetes complications, % (n/n-available/n-missing) | ||||
 Any microvascular disease | 20.7 (172/830/226) | 48.2 (389/807/23) | <0.001 | |
 Diabetic retinopathy | 6.1 (59/962/94) | 30.5 (249/816/15) | <0.001 | |
 Diabetic nephropathy | 15.4 (134/868/188) | 31.0 (253/816/15) | <0.001 | |
 Neuropathy | Unknown | 31.2 (238/762/68) | N/A | |
Family history, % (n/n-available/n-missing) | ||||
 First-degree relative with T2DM | 61.4 (586/955/101) | 68.2 (518/759/71) | 0.003 | |
 First-degree relative with CVD | 67.6 (608/899/157) | 69.2 (478/691/139) | 0.712 | |
 Any relative with early-onset CVD | 45.0 (436/968/88) | 45.0 (344/764/66) | 1.0 | |
Descent | ||||
 Caucasian descent, % (n/n-available/n-missing) | 90.3 (892/988/132 ) | 94.0 (721/767/63) | 0.005 | |
 Age of death father, year, median (IQR) | 73 (65–82) | 73 (65–82) | 0.728 | |
 Age of death mother, year, median (IQR) | 79 (72–87) | 77 (69–85) | 0.055 |